Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind Placebo-controlled Phase III Trial of TAP-144-SR (3M) in Spinal and Bulbar Muscular Atrophy (JASMITT)
jRCT2091220009Phase 3Completed
- Sponsor
- JASMITT
- Start
- Aug 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in spinal and bulbar muscular atrophy (SBMA) comparing TAP-144-SR (3M) with Placebo (2 arms). Primary endpoint: Pharyngeal barium residue (%) in videofluorography. Started Aug 2006; status: completed.
02
Drugs
leuprolide
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on jRCT2091220009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220009.